Famciclovir

Especificaciones

104227-87-4Número CAS

630-411-6Número CE

[2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetateNombre IUPAC

C14H19N5O4Fórmula química

321.33 g/molPeso molecular

famciclovir; 104227-87-4; Famvir; BRL-42810; Famciclovirum; BRL 42810; [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; DTXSID0023038; QIC03ANI02; 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine; NSC-758921; CHEBI:4974; 1,3-Propanediol, 2-(2-(2-amino-9H-purin-9-yl)ethyl)-, diacetate (ester); BRL42810; 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate (ester); 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine; DTXCID403038; 2-(2-(2-amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate; Acetic acid 2-acetoxymethyl-4-(2-amino-purin-9-yl)-butyl ester; 2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate (ester); (2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)butyl) acetate; 1,3-propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester); RefChem:55176; J05AB09; S01AD07; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)propane-1,3-diyl diacetate; Famciclovirum [INN-Latin]; 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate; C14H19N5O4; FCV; MFCD00866964; [2-(acetoxymethyl)-4-(2-aminopurin-9-yl)butyl] acetate; NCGC00095133-01; Oravir; 1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, 1,3-diacetate; 2-(2-(2-AMINO-9H-PURIN-9-YL)ETHYL)-1,3-PROPANEDIOL DIACETATE ESTER; 2-[2-(2-Amino-9H-purin-9-yl)ethyl]trimethylene diacetate;2-[2-(2-Amino-9H-purin-9-yl)ethyl]trimethylene diacetate; SMR000466375; Famvir (TN); CAS-104227-87-4; SR-01000759358; UNII-QIC03ANI02; Famciclovir [USAN:INN:BAN]; 2-[2-(2-Amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate ester; HSDB 8121; Famciclovir (Famvir); Famciclovir (Standard); Spectrum_000466; Valaciclovir Impurity A; FAMCICLOVIR [MI]; Spectrum2_001101; Spectrum3_001675; Spectrum4_000611; Spectrum5_001548; FAMCICLOVIR [INN]; FAMCICLOVIR [JAN]; FAMCICLOVIR [USAN]; CHEMBL880; FAMCICLOVIR [VANDF]; SCHEMBL2949; FAMCICLOVIR [MART.]; BSPBio_003489; FAMCICLOVIR [USP-RS]; FAMCICLOVIR [WHO-DD]; KBioGR_001162; KBioSS_000946; MLS000759505; MLS001424115; MLS006011896; Famciclovir (JAN/USP/INN); SPECTRUM1505201; SPBio_001202; orb1227074; orb1307910; Famciclovir - Bio-X trade mark; SCHEMBL29357294; Famciclovir, >=98% (HPLC); GTPL11629; KBio2_000946; KBio2_003514; KBio2_006082; KBio3_002709; FAMCICLOVIR [ORANGE BOOK]; GLXC-10567; HMS1922L09; HMS2051G22; HMS2090G10; HMS2093K12; HMS2232H09; HMS3262O08; HMS3370D14; HMS3393G22; HMS3656A04; HMS3715F03; HMS5081O07; Pharmakon1600-01505201; FAMCICLOVIR [USP MONOGRAPH]; ALBB-027262; Diacetyl 6-deoxy-9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine; MSK10595; Tox21_111442; Tox21_500793; AK-120; BDBM50248001; CCG-39277; EBC-07021; HY-17426R; NSC758921; s2467; STK623204; 2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate; AKOS005556609; Tox21_111442_1; AB07547; AC-8066; CS-1357; DB00426; FF23220; KS-5020; NC00156; NSC 758921; Famciclovir 100 |Ig/mL in Acetonitrile; NCGC00095133-02; NCGC00095133-03; NCGC00095133-04; NCGC00095133-06; NCGC00095133-15; NCGC00261478-01; BF164441; HY-17426; Famciclovir 100 microg/mL in Acetonitrile; SBI-0206743.P001; DB-014809; F0048; F0842; NS00009533; SW197536-3; D00317; EN300-120645; AB00639952-06; AB00639952-08; AB00639952_09; AB00639952_10; Q420186; SR-01000759358-4; SR-01000759358-5; 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-aminopurine; 9-[4-Acetox y-3-(acetoxymethyl)butyl]-2-aminopurine; BRD-K45033733-001-02-3; BRD-K45033733-001-05-6; BRD-K45033733-001-11-4; BRD-K45033733-001-12-2; Z1530532759; 9-[4-acetoxy-3-(acetoxymethyl)butyl]-2-amino-9h purine; 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-propane-1,3-diyl diacetate; Famciclovir, United States Pharmacopeia (USP) Reference Standard; Famciclovir, Pharmaceutical Secondary Standard; Certified Reference MaterialSinónimos